数据宝统计，截至09:54，三博脑科成交额42.41亿元，创上市以来新高。最新股价上涨10.67%，换手率 29.22%。上一交易日该股全天成交额为3.02亿元。（数据宝） （文章来源：证券时报网） ...

为深入落实健康中国战略,推动优质医疗资源下沉基层,让荣成百姓在家门口就能享受到国内顶尖专家的 诊疗服务,日前,由北京亦生中西医结合发展基金会主办的"燃希工程—2025强医公益行—山东荣成站"活 动在荣成市人民医院圆满举办。北京大学国际医院肿瘤微创科郑加生教授及专家团队、北京亦生中西医 结合发展基金会理事长谢丹亲临指导,荣成市卫生健康局党组成员、副局长丁健,荣成市人民医院党委书 记房建壮出席会议并致辞,荣成市人民医院副院长连俊杰主持活动。 在门诊楼2楼诊室,首都医科大学附属佑安医院肝病与肿瘤介入治疗中心张英华教授、北京大学国际医院 肿瘤微创科屈波教授耐心为前来咨询的肿瘤患者及高危人群提供免费初诊、介入诊疗咨询和病情评估服 务。在介入中心内,首都医科大学附属佑安医院肝病与肿瘤介入治疗中心的生守鹏教授、张英华教授,以 手术实操带教的形式开展教学活动。与此同时,北京大学国际医院肿瘤微创科郑加生教授前往病房进行 查房,针对诊疗过程中存在的问题提出优化建议,有效提升了医院医务人员对重点疾病的规范化诊疗能力, 为患者的后续治疗提供了有力保障。 下一步,郑加生教授团队将定期来荣为群众进行诊疗服务,切实把优质医疗资源留在基层, ...

Group 1 - The company announced the public transfer of 51% equity and debt of its subsidiary, Puluo New Energy Technology (Taixing) Co., Ltd., after receiving a letter from the Southwest United Property Rights Exchange following the sixth public listing [2] - The highest bid received was 101 yuan, which meets the listing conditions, and the transaction is now in the phase of soliciting the other shareholders' right of first refusal [2] - The initial listing price was 30.49 million yuan, which has been significantly reduced over six rounds of bidding, with the final listing price dropping to 1 yuan due to a lack of interested buyers in previous rounds [2] Group 2 - The company's main businesses include fluid control products, healthcare, and solar cell production [3] - Financial data indicates a continuous decline in revenue and an increase in losses, with total operating revenue of 582 million yuan and a net profit loss of 60.46 million yuan for the first three quarters of 2025 [3] - The company is projected to incur a total loss of 297 million yuan for the entire year of 2024 [3]

Group 1: Stock Trading and Market Reactions - Multiple commercial aerospace and brain-computer interface stocks announced either trading suspensions or risk warnings due to significant price fluctuations [1] - Guosheng Technology's stock will be suspended from trading starting January 7, 2026, after experiencing a cumulative increase of 370.20% from October 31, 2025, to January 6, 2026 [1][2] - The stock price of Guosheng Technology has risen over 512% since October 13, 2025, closing at 21.30 yuan per share with a total market capitalization of 14 billion yuan [4] Group 2: Company Announcements and Business Developments - Guosheng Technology has diversified into the photovoltaic sector and is acquiring stakes in companies related to high-precision lithium battery components [3] - Jiamai Packaging announced a stock price increase of 230.48% from December 17, 2025, to January 6, 2026, prompting a trading suspension for risk assessment [6] - Jiamai Packaging's main business remains focused on food and beverage packaging, with no significant changes reported [6] Group 3: Risk Warnings and Market Conditions - Fenglong Co. issued a warning after seven consecutive trading days of price increases, indicating a potential suspension if prices continue to rise [8][10] - The stock price of Fenglong Co. has deviated significantly from its fundamental value, with a cumulative increase of 94.92% since December 25, 2025 [12] - North Star Navigation noted that its stock price has fluctuated significantly, with commercial aerospace being just one of its application scenarios [14] Group 4: Industry Trends and Future Outlook - Aerospace Hangyu expects that revenue from commercial aerospace will account for less than 15% of its total revenue in 2025, highlighting a disconnect between stock performance and actual business operations [16] - China Satellite reported a stock price increase of 156.07% since December 3, 2025, significantly outpacing industry and market indices, indicating potential overvaluation [24][25] - Xiangyu Medical is focusing on non-invasive brain-computer interface technology, with no large-scale sales achieved as of the end of 2025 [26]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing a surge in investor interest, driven by technological breakthroughs and product approvals in China, alongside Elon Musk's announcement of mass production of BCI products by Neuralink within the year [1][3]. Industry Developments - The BCI industry is in a high-growth phase, supported by technological advancements, policy backing, and collaborative expectations within the robotics ecosystem, with projections indicating the global BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040 [3]. - Recent breakthroughs include the first clinical trial of a fully implanted, wireless BCI product by Brain Tiger Technology, which offers hope for patients with severe paralysis [3][4]. Company Responses - Multiple A-share listed companies have responded to the heightened interest in the BCI sector, with announcements detailing their business progress in this area [1][6]. - Xiangyu Medical reported a 44% cumulative increase in stock price, emphasizing its focus on non-invasive BCI technology, while acknowledging that its products have not yet achieved significant sales [6][9]. - Weisi Medical also clarified that its BCI products are in the early market cultivation stage and primarily focus on non-invasive technologies, with limited revenue contribution [9][10]. Strategic Collaborations - Companies are actively forming partnerships to enhance their BCI capabilities. Baiyang Pharmaceutical announced a collaboration with Capital Medical University to establish a joint laboratory focused on neuroscience and BCI research [11]. - Kefu Medical disclosed investments in non-invasive BCI robotics and implantable BCI companies, aiming for business synergy [11]. Technological Innovations - Companies like Sanbo Brain Science are making progress with their BCI technologies, including the development of a flexible microelectrode system for brain signal acquisition [12]. - In the semiconductor sector, companies are producing specialized chips for high-precision measurement of biological signals, which are essential for BCI applications [13]. Market Recognition - Domestic BCI products are gaining international recognition, with Shenzhou Rehabilitation's spinal interface product receiving breakthrough therapy designation from the FDA, marking a significant achievement for Chinese companies in the BCI field [4].

三博脑科（301293）(301293.SZ)公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内日收盘 价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。公司是以神经专科为特色的医疗服务集 团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的 研发、生产及销售，神经调控技术带来的收入占公司营业收入比重很小，对公司业绩基本没有影响。 ...

Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]

Group 1 - The core viewpoint of the news is that Tongce Medical (600763) has shown a slight increase in stock price and has reported positive financial performance in its recent quarterly results [1][2] - As of January 6, 2026, Tongce Medical's stock closed at 41.29 yuan, with a trading volume of 79,900 hands and a total transaction amount of 329 million yuan [1] - In the recent funding flow data, the main funds experienced a net outflow of 9.82 million yuan, while retail investors saw a net inflow of 10.79 million yuan, indicating a mixed sentiment among different investor groups [1] Group 2 - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up 3.16% year-on-year [2] - The company's third-quarter results showed a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34%, and a net profit of 192 million yuan, up 2.31% year-on-year [2] - The company has a debt ratio of 25.1%, with investment income of 41.22 million yuan and financial expenses of 31.93 million yuan, while maintaining a gross profit margin of 41.69% [2]

Core Insights - Elon Musk announced plans for mass production of brain-computer interface (BCI) products within the year, igniting investor enthusiasm in the BCI sector [1] - Recent technological breakthroughs and product approvals in China's BCI industry have bolstered confidence in its growth [1] Market Performance - The BCI sector experienced a surge, with multiple companies hitting their daily price limits, including BeiYikang with a 69% increase over two days [1] - Notable stock performances include: - BeiYikang: +29.98% at 58.44 - WeiSi Medical: +20.01% at 69.70 - Sanbo Brain Science: +20.01% at 84.94 - AiPeng Medical: +20.00% at 39.96 - Xiangyu Medical: +20.00% at 87.12 [2] Technological Advancements - The BCI technology is transitioning from laboratory research to clinical and industrial applications, driven by technological breakthroughs and policy support [3] - McKinsey predicts the global BCI medical application market could reach $40 billion by 2030 and $145 billion by 2040 [3] - Domestic companies like Brain Tiger Technology have achieved significant milestones, including the first clinical trial of a fully implanted, wireless BCI product [3][4] Company Developments - Several A-share listed companies have responded to the heightened interest in BCI, emphasizing their early-stage involvement in the sector [5][10] - Xiangyu Medical reported a 44% cumulative increase in stock price and highlighted its focus on non-invasive BCI technologies [6][9] - WeiSi Medical and Sanbo Brain Science both noted that their BCI products are still in the early stages of market development, with limited revenue contribution [9][10] Collaborative Efforts - Companies are forming partnerships to advance BCI research, such as Baiyang Pharmaceutical's collaboration with Capital Medical University [11] - Kuofu Medical has invested in non-invasive BCI robotics and previously in implantable BCI companies, indicating a strategic approach to market entry [11] Industry Participation - Various sectors, including semiconductors and new materials, are leveraging their technological strengths to capitalize on BCI opportunities [12][13] - Companies like Yiwai Lithium Energy and Lens Technology are collaborating with leading BCI firms to enhance their product offerings [13]

本报讯（记者 陈强 孙乐琪）昨天上午，首都医科大学宣武医院房山院区暨国家医学中心建设工程建设 动员会在房山区长阳镇举行，标志着该项目正式启动建设。作为本市重点推进的公共服务工程，项目预 计2029年投用，建成后将成为房山区首家三级甲等综合医院，有效提升京西南优质医疗服务能力。 宣武医院现址位于西城区，此次启动的房山院区东片区占地14.3万平方米，总建筑面积19.89万平方米， 规划床位800张。 宣武医院房山院区将打造集智慧、韧性、绿色于一体的"智慧健康生态综合体"。建筑设计独具匠心，南 北两组主体建筑通过放射状交通体系连接中央大厅，形成高效诊疗动线，实现临床、教学、科研、康复 等功能区无缝衔接。这一设计形似神经元共生形态，既凸显了宣武医院在神经科学领域的特色优势，也 为多学科协同发展提供支撑。 智慧医疗是新院区一大亮点。宣武医院房山院区将搭建与宣武医院西城院区同源的数字化诊疗平台，全 面落地远程会诊、人工智能辅助诊断等技术，并引入核磁共振等尖端医疗设备。同时深度融合"互联网 +医疗"模式，患者通过"掌上宣武医院"平台，即可完成在线复诊、医保实时结算、药品配送到家等全流 程服务。 该院区距离地铁房山线广阳城站 ...